Published in Obesity and Diabetes Week, September 4th, 2006
"Increasing evidence supports a negative role of glycogen synthase kinase-3 (GSK-3) in regulation of skeletal muscle glucose transport. We assessed the effects of chronic treatment of insulin-resistant, prediabetic obese Zucker (fa/fa) rats with a highly selective GSK-3 inhibitor (CT118637) on glucose tolerance, whole body insulin sensitivity, plasma lipids, skeletal muscle insulin signaling, and in vitro skeletal muscle glucose transport activity," researchers in the United States report.
B.B. Dokken and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week